FluNet

FluNet
Name	FluNet
Type	Surveillance platform
Owner	World Health Organization
Launched	1997
Purpose	Influenza virological surveillance

FluNet is a global virological surveillance platform operated by the World Health Organization to track seasonal and pandemic influenza activity through laboratory-confirmed data. The platform aggregates reports from national influenza centres, regional laboratories, and public health institutes to inform risk assessment, vaccine composition, and outbreak response across countries and territories. FluNet interoperates with other WHO systems and international networks to support decision-making by agencies such as the United Nations, European Centre for Disease Prevention and Control, and national ministries of health.

Overview

FluNet provides time series of virological data including virus type, subtype, lineage, and antigenic characterizations submitted by participating laboratories such as National Influenza Centres (WHO Global Influenza Surveillance and Response System), Centers for Disease Control and Prevention, Public Health England, Institut Pasteur, and National Institute for Viral Disease Control and Prevention (China). The platform supports public health stakeholders including ministry of health officials, vaccine manufacturers like GlaxoSmithKline, Sanofi Pasteur, and Seqirus, and research institutions such as Imperial College London and Johns Hopkins Bloomberg School of Public Health. FluNet data feed into vaccine strain selection meetings convened by WHO collaborating centres including WHO Collaborating Centre for Reference and Research on Influenza, London and WHO Collaborating Centre for Reference and Research on Influenza, Atlanta. The system interfaces with global initiatives such as Global Influenza Surveillance and Response System (GISRS), Global Health Security Agenda, and International Health Regulations (2005)-related activities.

History and development

FluNet originated from surveillance efforts coordinated by WHO and its Regional Office for Europe, Regional Office for the Americas (PAHO), and Regional Office for Africa during the late 20th century, building on laboratory networks created after the 1957 influenza pandemic and the 1968 influenza pandemic. Technical development drew on contributions from collaborators including Centers for Disease Control and Prevention (United States), MRC Centre for Outbreak Analysis and Modelling, and national reference laboratories in Japan, Australia, and France. The platform evolved alongside milestones such as the 2009 swine flu pandemic (H1N1), prompting enhancements in data timeliness and antigenic characterization reporting. Partnerships with organizations like Gavi, the Vaccine Alliance, Bill & Melinda Gates Foundation, and World Bank supported capacity building in low- and middle-income countries including India, Brazil, and South Africa.

Data collection and methodology

FluNet receives standardized laboratory reports from participating nodes including National Influenza Centres, WHO collaborating centres, and subnational public health laboratories such as State Public Health Laboratories (United States). Reports include counts of specimens tested, positive detections by virus type and subtype, and occasional genomic or antigenic data generated by sequencing centres like Sanger Institute and Wellcome Trust Sanger Institute collaborators. Laboratories follow protocols established by organizations such as WHO Global Influenza Programme, European Centre for Disease Prevention and Control, and quality assurance schemes run by WHO Collaborating Centre, Melbourne. Data are aggregated weekly, harmonized across diverse diagnostic platforms including real-time PCR assays developed by the CDC Influenza Division and antigenic assays performed at reference centres such as CDC Influenza Reagent Resource. FluNet metadata capture laboratory identifiers, specimen collection dates, and patient age strata used by modelling groups at London School of Hygiene & Tropical Medicine and Columbia University Mailman School of Public Health.

Global coverage and participating networks

The network underpinning FluNet spans WHO regional networks including WHO Regional Office for Europe, WHO Regional Office for the Eastern Mediterranean, WHO Regional Office for the Western Pacific, WHO Regional Office for South-East Asia, and WHO Regional Office for Africa. Key laboratory partners include national institutes like Robert Koch Institute, National Institute for Communicable Diseases (South Africa), National Institute of Infectious Diseases (Japan), FIOCRUZ in Brazil, and Indian Council of Medical Research (ICMR). FluNet connects with complementary platforms and consortia such as GISAID, Global Initiative on Sharing Avian Influenza Data, Nextstrain, and regional surveillance systems run by ECDC and PAHO. Data contributors range from high-capacity centres like CDC Atlanta and National Institute for Biological Standards and Control to sentinel hospital networks associated with universities including University of Toronto and University of Cape Town.

Uses and public health impact

FluNet informs WHO vaccine composition consultations attended by representatives from WHO Collaborating Centres, European Vaccine Manufacturers, and regulatory bodies such as European Medicines Agency and U.S. Food and Drug Administration. Public health responses informed by FluNet include seasonal vaccination strategy adjustments in countries like United Kingdom, Japan, and Chile, and pandemic risk assessments used by national emergency committees such as those convened under International Health Regulations (2005). Researchers use FluNet outputs in modelling studies from groups at Imperial College London, University of Oxford, and Harvard T.H. Chan School of Public Health to estimate burden, transmissibility, and vaccine effectiveness. FluNet data have supported publications in journals like The Lancet, Nature Medicine, and BMJ and informed policy reports from agencies including WHO, World Bank, and UNICEF.

Limitations and challenges

FluNet faces limitations common to global surveillance: variable laboratory capacity across countries such as Somalia, Nepal, and Haiti; reporting delays experienced during the 2014 Ebola epidemic and the COVID-19 pandemic; and heterogeneity in sentinel sampling designs used by institutions like sentinel surveillance networks and national laboratories. Integration with genomic platforms such as GISAID and phylogenetic analyses via Nextstrain is constrained by uneven sequencing throughput in regions serviced by African Centre of Excellence for Genomics of Infectious Disease. Data interpretation can be complicated by co-circulation of pathogens monitored by agencies including WHO and ECDC, and by shifts in healthcare seeking observed in outbreaks like SARS, MERS, and COVID-19 pandemic. Addressing these challenges involves capacity-building partnerships with WHO Regional Offices, technical assistance from CDC, and investment from donors such as Gavi, the Vaccine Alliance and Bill & Melinda Gates Foundation.

Category:Influenza surveillance